* Positive phase III results for Genentech's emicizumab in hemophilia A published in the New England Journal Of Medicine

* Genentech says haven 1 showed emicizumab reduced bleed rate by 87 percent compared with on-demand bypassing agents

* Genentech says all 12 secondary endpoints in haven 1 were positive

* Genentech says data from haven 1 and haven 2 have been submitted for approval consideration to U.S. FDA and European Medicines Agency (EMA) Source text for Eikon: Further company coverage: